These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
344 related articles for article (PubMed ID: 25275021)
1. Promise of combining a Bcl-2 family inhibitor with bortezomib or SAHA for adult T-cell leukemia/lymphoma. Kunami N; Katsuya H; Nogami R; Ishitsuka K; Tamura K Anticancer Res; 2014 Oct; 34(10):5287-94. PubMed ID: 25275021 [TBL] [Abstract][Full Text] [Related]
2. Targeting Bcl-2 family proteins in adult T-cell leukemia/lymphoma: in vitro and in vivo effects of the novel Bcl-2 family inhibitor ABT-737. Ishitsuka K; Kunami N; Katsuya H; Nogami R; Ishikawa C; Yotsumoto F; Tanji H; Mori N; Takeshita M; Miyamoto S; Tamura K Cancer Lett; 2012 Apr; 317(2):218-25. PubMed ID: 22138435 [TBL] [Abstract][Full Text] [Related]
3. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B. Rooswinkel RW; van de Kooij B; Verheij M; Borst J Cell Death Dis; 2012 Aug; 3(8):e366. PubMed ID: 22875003 [TBL] [Abstract][Full Text] [Related]
4. The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Paoluzzi L; Gonen M; Bhagat G; Furman RR; Gardner JR; Scotto L; Gueorguiev VD; Heaney ML; Manova K; O'Connor OA Blood; 2008 Oct; 112(7):2906-16. PubMed ID: 18591385 [TBL] [Abstract][Full Text] [Related]
5. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386 [TBL] [Abstract][Full Text] [Related]
6. The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis. Zhang QL; Wang L; Zhang YW; Jiang XX; Yang F; Wu WL; Janin A; Chen Z; Shen ZX; Chen SJ; Zhao WL Leukemia; 2009 Aug; 23(8):1507-14. PubMed ID: 19282831 [TBL] [Abstract][Full Text] [Related]
7. Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1. Chen S; Dai Y; Pei XY; Grant S Mol Cell Biol; 2009 Dec; 29(23):6149-69. PubMed ID: 19805519 [TBL] [Abstract][Full Text] [Related]
8. SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib. Emanuele S; Lauricella M; Carlisi D; Vassallo B; D'Anneo A; Di Fazio P; Vento R; Tesoriere G Apoptosis; 2007 Jul; 12(7):1327-38. PubMed ID: 17351739 [TBL] [Abstract][Full Text] [Related]
9. Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy. Karlsson H; Lindqvist AC; Fransson M; Paul-Wetterberg G; Nilsson B; Essand M; Nilsson K; Frisk P; Jernberg-Wiklund H; Loskog A Cancer Gene Ther; 2013 Jul; 20(7):386-93. PubMed ID: 23788110 [TBL] [Abstract][Full Text] [Related]
10. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma. Heider U; Rademacher J; Lamottke B; Mieth M; Moebs M; von Metzler I; Assaf C; Sezer O Eur J Haematol; 2009 Jun; 82(6):440-9. PubMed ID: 19220424 [TBL] [Abstract][Full Text] [Related]
11. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation. Kang MH; Wan Z; Kang YH; Sposto R; Reynolds CP J Natl Cancer Inst; 2008 Apr; 100(8):580-95. PubMed ID: 18398104 [TBL] [Abstract][Full Text] [Related]
12. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis. Miller LA; Goldstein NB; Johannes WU; Walton CH; Fujita M; Norris DA; Shellman YG J Invest Dermatol; 2009 Apr; 129(4):964-71. PubMed ID: 18987671 [TBL] [Abstract][Full Text] [Related]
13. ABT-737 synergizes with bortezomib to induce apoptosis, mediated by Bid cleavage, Bax activation, and mitochondrial dysfunction in an Akt-dependent context in malignant human glioma cell lines. Premkumar DR; Jane EP; DiDomenico JD; Vukmer NA; Agostino NR; Pollack IF J Pharmacol Exp Ther; 2012 Jun; 341(3):859-72. PubMed ID: 22393246 [TBL] [Abstract][Full Text] [Related]
14. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Chauhan D; Velankar M; Brahmandam M; Hideshima T; Podar K; Richardson P; Schlossman R; Ghobrial I; Raje N; Munshi N; Anderson KC Oncogene; 2007 Apr; 26(16):2374-80. PubMed ID: 17016430 [TBL] [Abstract][Full Text] [Related]
15. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Pei XY; Dai Y; Grant S Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093 [TBL] [Abstract][Full Text] [Related]
16. Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines. Hui KF; Leung YY; Yeung PL; Middeldorp JM; Chiang AK Br J Haematol; 2014 Dec; 167(5):639-50. PubMed ID: 25155625 [TBL] [Abstract][Full Text] [Related]
17. ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway. Li R; Zang Y; Li C; Patel NS; Grandis JR; Johnson DE Mol Pharmacol; 2009 May; 75(5):1231-9. PubMed ID: 19246337 [TBL] [Abstract][Full Text] [Related]
18. Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids. Yang TM; Barbone D; Fennell DA; Broaddus VC Am J Respir Cell Mol Biol; 2009 Jul; 41(1):14-23. PubMed ID: 19097992 [TBL] [Abstract][Full Text] [Related]
19. The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors. Jóna A; Khaskhely N; Buglio D; Shafer JA; Derenzini E; Bollard CM; Medeiros LJ; Illés A; Ji Y; Younes A Exp Hematol; 2011 Oct; 39(10):1007-1017.e1. PubMed ID: 21767511 [TBL] [Abstract][Full Text] [Related]
20. Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737. Okumura K; Huang S; Sinicrope FA Clin Cancer Res; 2008 Dec; 14(24):8132-42. PubMed ID: 19088028 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]